Therefore, there is a clear need for the quantitative assessment of both wild-type and mutant IDH expression, together with potential alterations in the CCT complex, as this combined analysis may provide deeper insights into glioblastoma biology. This evidence concerns the gene IDH2 and glioblastoma.